Detail akcie Heron Therapeutics online

Business Summary: Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Heron Therapeutics Inc revenues decreased 11% to $34.7M. Net loss totaled $8.1M vs. income of $2.6M. Revenues reflect CINVANTI segment decrease of 20% to $20.5M, SUSTOL segment decrease of 81% to $547K. Net loss reflects United States segment loss totaling $4.8M vs. income of $3.2M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.01717 to -$0.04277.